The Profile of Mood States (POMS; McNair, Lorr, & Droppleman) is widely used to assess mood states. However, the utility of the POMS has been restricted by the lack of normative data from the general population. We report on our adult (N = 400) and geriatric (N = 170) POMS standardization samples. Both groups were age-, gender-, and race-stratified according to 1990 census data. We also report on convergent and discriminant validity of POMS scales, using a multitrait, multimethod paradigm.
Memory disturbance is common in patients with multiple sclerosis (MS), as previously demonstrated on clinical memory tests of explicit learning using effortful retrieval paradigms. To better understand the mechanisms underlying memory failure, we compared the performance of 46 MS patients and 47 demographically matched normal controls on experimental tests of working memory, semantic encoding, and implicit memory. On the working memory task, MS patients demonstrated an exaggerated word length effect, which indicates a deficit in the control process of articulatory rehearsal. In contrast, MS patients demonstrated a normal buildup and release from proactive inhibition, which suggests intact semantic encoding. Finally, on priming and procedural memory tasks, MS patients performed without difficulty. The MS patients' test performance was not correlated with illness duration or course, severity of physical disability, or psychoactive medication use.Memory impairment is the most common form of cognitive dysfunction observed in patients with multiple sclerosis (MS). From 40% to 60% of MS patients perform below expectations on learning and memory
We administered the Multiscale Depression Inventory (MDI) and the Beck Depression Inventory (BDI) to 84 multiple sclerosis (MS) patients, 101 patients diagnosed with major depression and 87 nonmedical, nonpsychiatric controls. The MDI consists of three separate depression scales measuring mood, vegetative, and evaluative symptoms. We found that: (a) MS patients did not significantly differ from the controls in mood symptoms, (b) the depression prevalence rate in MS patients was significantly lower when measured by the mood scale (17·7%) than by the BDI (30·5%) or MDI total score (26·6%), and (c) MS patients showed significantly less mood disturbance than a non-MS comparison group matched on BDI measured depression severity. We suggest that the inclusion of nonmood symptoms in self-report depression scales may artificially raise both prevalence rates and severity ratings of MS related depression and that the most valid measure of depression in MS is mood disturbance. (JINS, 1995, I, 291–296.)
Current self-report depression scales may overestimate depression symptoms in medical patients by including items measuring symptoms inherent to many medical conditions. They may therefore reflect a patient's medical rather than psychological state. We present the Chicago Multiscale Depression Inventory (CMDI), a factorially derived self-report depression scale that includes Mood, Evaluative, and Vegetative subscales. The CMDI and its subscales were designed to be used separately or combined; we posit that the nonvegetative CMDI subscales are the most accurate means of examining depression in medical patients. In this study we outline the development, standardization, and initial validation of the CMDI, a multistep process that required a total sample of 1,062 adults. We show the CMDI and each of its subscales to be internally consistent, reliable, and valid. Confirmatory factor analysis supports the CMDI factor structure. Finally, we report standardization scores for each of the CMDI scales, derived from an age-, race- and gender-stratified standardization sample of 420 adults.
scite is a Brooklyn-based organization that helps researchers better discover and understand research articles through Smart Citations–citations that display the context of the citation and describe whether the article provides supporting or contrasting evidence. scite is used by students and researchers from around the world and is funded in part by the National Science Foundation and the National Institute on Drug Abuse of the National Institutes of Health.